Advances and future directions in the targeting of HER2-positive breast cancer: implications for the future
IM Subbiah, AM Gonzalez-Angulo - Current treatment options in oncology, 2014 - Springer
IM Subbiah, AM Gonzalez-Angulo
Current treatment options in oncology, 2014•SpringerOpinion statement The natural history of HER2-positive breast cancer significantly changed
in the past 15 years. Form being the most aggressive type of breast cancer, it became
treatable with important cure rates. However, with new and successful drugs, resistance
emerges. Progress in research and drug development continues to make available effective
anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the
data that support the indications of each compound and to continue clinical trial …
in the past 15 years. Form being the most aggressive type of breast cancer, it became
treatable with important cure rates. However, with new and successful drugs, resistance
emerges. Progress in research and drug development continues to make available effective
anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the
data that support the indications of each compound and to continue clinical trial …
Opinion statement
The natural history of HER2-positive breast cancer significantly changed in the past 15 years. Form being the most aggressive type of breast cancer, it became treatable with important cure rates. However, with new and successful drugs, resistance emerges. Progress in research and drug development continues to make available effective anti-HER2 therapies. Our challenge today is to use these tools correctly by looking at the data that support the indications of each compound and to continue clinical trial participation.
Springer